Kenya has successfully gotten a new drug that can be applied at least twice a week.
In addition, it will also require patients to partake yearly booster shots costing Ksh4.7 million each.
the drug known as Sunlenca will be applied to adult patients only According to the United States Food and Drug Administration (FDA).
The drug functions by obstructing the capsid protein coat of the HIV-1 virus, interfering with the viral life cycle.
According to a report by Worlds Aid (2022), Kenya recorded an increase in new HIV infections for the first time in a decade with more than 2,000 cases from 32,025 in 2021 to 34,540 in 2022 with a total of at least 1.4 million Kenyans living with HIV.